Dr. Chi is a senior pharmacologist and toxicologist in the Division of Cardiovascular and Renal Products at the Office of New Drugs, USFDA. Prior to that, she was a senior consultant and Subject Matter Expert in the Federal Healthcare Practice at Deloitte Consulting LLP. She is specialized in analyzing data from toxicological, pharmacological and clinical studies of new drug submissions indicated for cardiovascular and renal diseases, and giving scientific and regulatory recommendations. Dr. Chi received her Ph.D. degree in Cardiovascular Sciences from Baylor College of Medicine and had postdoctoral training in pharmacogenomics and pathology in cardio-renal diseases at Columbia University, supported by a fellowship from American Heart Association. She received her M.D. degree from Capital University of Medical Sciences in Beijing China. Dr. Chi has published more than 25 papers on peer-reviewed journals in her field and has received several research awards.

Dr. Xuan Chi his research interest are Cardiac stem cells, biomarkers for heart failure and renal injuries, oligonucleotide therapeutics, tissue chips